RoosterBio has partnered with the U.S. Army to research and develop stem cell-based treatments for soldiers who suffered from limb loss, severe burns and other trauma-related injuries.
The U.S. Army Institute of Surgical Research and RoosterBio will explore the potential use of mesenchymal stem cells in regenerative medicine and acute trauma care applications under the three-year cooperative research and development agreement, the company said Wednesday.
RoosterBio will share its experience in large-scale MSC production with USAISR“™s analytical testing experience and research on MSC functions in an effort to support future clinical trials.
“This collaboration ensures the maintenance of critical stem cell functions needed for robust clinical translation of ‘off-the-shelf’ products, designed for trauma applications,“ said Jon Rowley, CEO of RoosterBio.
Rowley will serve as co-principal investigator and will work with Lt. Col. Andrew Cap and his team at USAISR“™s Blood Research Program as part of the agreement.
Frederick, Maryland-based RoosterBio develops large volumes of adult human MSCs in combination with engineered media platforms to help facilitate experiments on stem cell-based therapies.